Last updated: October 02, 2026

Application No. 18/699,454

STEREOCILIN PROMOTERS AND USES THEREOF

Non-Final OA

Filed

Apr 08, 2024

Priority

Oct 12, 2021 — provisional 63/254,930 +3 more

Examiner

MOLOYE, TITILAYO

Art Unit

Tech Center

Assignee

Regeneron Pharmaceuticals Inc.

OA Round

1 (Non-Final)

This examiner grants 62% of cases after interview

— +47.9% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 554 resolved cases, 2023–2026

Examiner Intelligence

MOLOYE, TITILAYO View full profile →

Grants 62% of resolved cases

Career Allowance Rate

346 granted / 554 resolved

+2.5% vs TC avg

Strong +48% interview lift

Without

With

+47.9%

Interview Lift

resolved cases with interview

Typical timeline

3y 8m

Avg Prosecution

47 currently pending

Career history

591

Total Applications

across all art units

Statute-Specific Performance

§101

4.4%

-35.6% vs TC avg

§103

40.2%

+0.2% vs TC avg

§102

11.1%

-28.9% vs TC avg

§112

31.9%

-8.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 554 resolved cases

Prosecution Timeline

Apr 08, 2024

Application Filed

Sep 16, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/443,786

Patent 12734197

Generation Of Uniform Hepatocytes From Human Embryonic Stem Cells By Inhibiting TGF-BETA and Methods Of Maintaining Hepatic Cultures

5y 1m to grant Granted Sep 15, 2026

17/846,446

Patent 12698339

ANTI-GLYPICAN-1-IMMUNIZING ANTIGEN RECEPTOR

4y 1m to grant Granted Aug 04, 2026

17/044,157

Patent 12680062

FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONE

5y 9m to grant Granted Jul 14, 2026

17/956,771

Patent 12667088

ANIMAL MODEL OF BRAIN TUMOR AND MANUFACTURING METHOD OF ANIMAL MODEL

3y 9m to grant Granted Jun 30, 2026

17/264,939

Patent 12661385

MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION

5y 4m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

62%

Grant Probability

99%

With Interview (+47.9%)

3y 8m (~1y 2m remaining)

Median Time to Grant

Low

PTA Risk

Based on 554 resolved cases by this examiner. Grant probability derived from career allowance rate.